-- Robert Langer, Sc.D.: Institute Professor of Chemical and Biomedical
Engineering, Massachusetts Institute of Technology
-- Ram Sasisekharan, Ph.D.: Professor of Biological Engineering & Health
Sciences and Technology, Massachusetts Institute of Technology
-- Ben Shapiro, M.D.: Retired Executive Vice President of Worldwide Basic
Research, Merck Research Laboratories
"Fate's timing is excellent," said Fate's Executive Vice President Tom St. John. "The science is now mature enough. Clear therapeutic modalities have emerged, and the cloud of political and ethical debate surrounding embryonic stem cells is now a thing of the past. We've got a real opportunity to prove that Fate's adult stem cell therapies are the future of medicine."
Before joining Fate, St. John was the Vice President of Therapeutic Development at ICOS Corporation overseeing all of ICOS' development programs.
World-class investment team lined up behind scientists
The unparalleled scientific team is backed by leading venture capital firms ARCH Venture Partners, Polaris Venture Partners, Venrock and OVP, all with successful track records in building some of the world's leading life sciences companies.
The syndicate group has a combined $7 billion under management. Ground-breaking biotechnology companies founded by the firms and their partners include Immunex, IDEC Pharmaceuticals, Gilead Sciences, Genetics Institute, Illumina, Centocor, Sepracor, Alnylam Pharmaceuticals, Athena Neurosciences, Aviron, Corixa, deCode Genetics, Geron, Glycofi, Ikaria, Millennium Pharmaceuticals, Momenta Pharmaceuticals, Sirna Therapeutics, Trubion Pharmaceuticals, Vical and XenoPort.
Fate Therapeutics was co-founded by Alex Rives, of ARCH Venture
Partners. The company's board of directors includes Amir Nashat, General
|SOURCE Fate Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved